Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEMULEN 1/35-21 vs ADQUEY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing ethinyl estradiol (estrogen) and ethynodiol diacetate (progestin). Inhibits gonadotropin secretion (FSH, LH) via negative feedback on hypothalamic-pituitary axis, suppressing ovulation. Additionally, thickens cervical mucus and alters endometrial receptivity.
ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.
Prevention of pregnancy,Treatment of moderate acne vulgaris in women at least 15 years old who have achieved menarche and are seeking contraception,Oral contraceptive for women over 35 who smoke (off-label: not recommended due to increased cardiovascular risk)
Alzheimer disease (FDA approved for treatment of mild cognitive impairment or mild dementia stage),Off-label: none established
One tablet orally once daily for 21 days, followed by 7 days off. Each tablet contains 1 mg ethynodiol diacetate and 35 mcg ethinyl estradiol.
400 mg orally once daily with food.
Ethinyl estradiol: 13±3 hours (terminal); norethindrone: 8±3 hours. Steady-state achieved after ~5 days.
Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours in Cr Cl <30 m L/min)
Ethinyl estradiol: primarily metabolized by CYP3A4 hydroxylation and conjugation; undergoes enterohepatic recirculation. Ethynodiol diacetate: rapidly deacetylated to norethindrone, which is metabolized by CYP3A4 and CYP2C9; undergoes reduction, hydroxylation, and conjugation.
Metabolized via catabolic pathways similar to endogenous Ig G; no specific cytochrome P450 enzyme involvement.
Renal (primarily as glucuronide and sulfate conjugates): ~60%; fecal: ~40%
Renal: 70-80% unchanged; Fecal: 5-10% as metabolites; Biliary: minimal (<2%)
Ethinyl estradiol: 97–98% bound to albumin; norethindrone: 93–97% bound to albumin and SHBG
98% bound to albumin
Ethinyl estradiol: 2.5–4 L/kg; norethindrone: 3.5–5 L/kg. Indicates extensive tissue distribution.
0.2-0.3 L/kg; indicates limited extravascular distribution
Ethinyl estradiol: ~45% (first-pass metabolism); norethindrone: ~65% (first-pass metabolism). Oral administration only.
Oral: 85-90%; IM: 95-100%
No dose adjustment required for renal impairment. However, caution in severe renal impairment due to potential fluid retention.
Cr Cl ≥60 m L/min: no adjustment; Cr Cl 30-59 m L/min: 200 mg daily; Cr Cl <30 m L/min: 100 mg daily; hemodialysis: 100 mg daily after dialysis.
Contraindicated in Child-Pugh class B and C (moderate to severe hepatic impairment). Use with caution in mild impairment (Child-Pugh A) with monitoring.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg daily; Child-Pugh C: not recommended.
Not indicated for use before menarche. Post-menarche: use same dosing as adults; monitor for bone health and growth.
Weight ≥10 kg: 12 mg/kg/dose twice daily; weight <10 kg: 8 mg/kg/dose twice daily.
Not indicated for use in postmenopausal women due to lack of efficacy and increased thromboembolic risk.
Initial dose 200 mg daily; titrate based on renal function; monitor for neuropsychiatric effects.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Amyloid-related imaging abnormalities (ARIA), including ARIA-E (edema/effusion) and ARIA-H (hemosiderin deposition), can occur. ARIA is usually asymptomatic but serious events including seizure and status epilepticus have been reported. Patients with apolipoprotein E ε4 homozygosity have a higher incidence of ARIA.
Increased risk of thromboembolic disorders (e.g., stroke, DVT, PE),Increased risk of myocardial infarction, especially in smokers and women with hypertension or hyperlipidemia,Hepatic neoplasia (benign/malignant),Gallbladder disease,Hypertension,Carbohydrate and lipid metabolism changes,Ocular lesions (e.g., retinal thrombosis),Depression,Fluid retention,Irregular bleeding,Possible reduced efficacy with enzyme-inducing drugs (e.g., rifampin, anticonvulsants),Chloasma,Pregnancy (should be ruled out before use)
1) Amyloid-related imaging abnormalities (ARIA): monitor with MRI before and during treatment; consider dose interruption or discontinuation if severe. 2) Hypersensitivity reactions: angioedema, urticaria reported. 3) Risk of falls due to cognitive impairment. 4) No head-to-head trials showing superiority over other treatments.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Known or suspected estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Benign or malignant liver tumor (current or history),Severe hepatic impairment or acute liver disease,Hypersensitivity to any component,Age over 35 and smoking (≥15 cigarettes/day),Uncontrolled hypertension (systolic ≥160 mm Hg or diastolic ≥100 mm Hg),Diabetes with vascular involvement,Migraine with focal aura (if age ≥35),Major surgery with prolonged immobilization
History of severe hypersensitivity to aducanumab or any excipients in ADQUEY.
No significant food interactions. Grapefruit juice may slightly increase estrogen levels but not clinically relevant. Avoid St. John's Wort as it reduces contraceptive efficacy. No dietary restrictions.
Avoid grapefruit and grapefruit juice; may increase drug levels. High-fat meals can increase absorption; take with food or on an empty stomach consistently.
First trimester: increased risk of cardiovascular defects (RR ~1.3) and oral clefts (RR ~1.1) with exposure; second and third trimesters: no proven association with major malformations, but may cause masculinization of female genitalia if high doses of progestins (ethynodiol diacetate is a weak progestin, risk low). Postnatal: potential for neonatal jaundice (due to estrogen).
ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Second and third trimester exposure may lead to feminization of male fetuses and other adverse outcomes.
Excreted in breast milk in small amounts (estrogen and progestin levels ~1% of maternal dose; M/P ratio not well defined). May reduce milk quality and quantity; use only if benefits outweigh risks, preferably after weaning.
Excretion into breast milk is minimal; however, ADQUEY may reduce milk production and quality. M/P ratio not established. Avoid use during breastfeeding.
No dose adjustments; contraindicated during pregnancy due to fetal risks. If used inadvertently, discontinue immediately.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue immediately if pregnancy occurs.
Demulen 1/35-21 (ethinyl estradiol 35 mcg, ethynodiol diacetate 1 mg) is a monophasic combined oral contraceptive. It has lower estrogen dose than many older pills but still carries thromboembolic risk. Advise patients to take at same time daily. Missed pill protocols: if missed >12 hours, take pill ASAP and continue; if missed 2 or more pills, use backup contraception for 7 days. Consider non-contraceptive benefits: improved cycle regularity, reduced dysmenorrhea, decreased acne. Monitor blood pressure and liver function. Contraindications: history of DVT/PE, active liver disease, breast cancer, pregnancy, migraine with aura. Smoking increases thromboembolic risk significantly, especially in women >35.
Administration with a full glass of water and staying upright for 30 minutes reduces risk of esophagitis. Monitor for cutaneous lupus erythematosus and Stevens-Johnson syndrome. Avoid concomitant use with drugs that prolong QT interval due to risk of torsades de pointes.
Take one pill daily at the same time for 21 days, then no pills for 7 days; you will have withdrawal bleeding during the free week.,If you miss a pill by less than 12 hours, take it immediately and continue on schedule. If more than 12 hours, take the missed pill and use backup contraception (condoms) for the next 7 days.,Common side effects include nausea, headache, breast tenderness, breakthrough bleeding, and mood changes; these often improve after the first few months.,Seek medical help for symptoms of blood clots: sudden leg pain/swelling, chest pain, shortness of breath, sudden severe headache or vision changes.,Do not smoke while taking this medication; smoking increases risk of serious cardiovascular side effects, especially if over 35.,This pill does not protect against sexually transmitted infections; use condoms for STI prevention.
Take exactly as prescribed; do not double doses if missed.,Swallow tablet whole; do not crush or chew.,Avoid direct sunlight; use sunscreen and protective clothing.,Report any skin rash, blisters, or eye irritation immediately.,Do not take with antacids, iron supplements, or sucralfate; separate by at least 4 hours.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEMULEN 1/35-21 vs ADQUEY, answered by our medical review team.
DEMULEN 1/35-21 is a Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol (estrogen) and ethynodiol diacetate (progestin). Inhibits gonadotropin secretion (FSH, LH) via negative feedback on hypothalamic-pituitary axis, suppressing ovulation. Additionally, thickens cervical mucus and alters endometrial receptivity.. ADQUEY is a Oral Contraceptive that works by ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEMULEN 1/35-21 and ADQUEY depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEMULEN 1/35-21 is: One tablet orally once daily for 21 days, followed by 7 days off. Each tablet contains 1 mg ethynodiol diacetate and 35 mcg ethinyl estradiol.. The standard adult dose of ADQUEY is: 400 mg orally once daily with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEMULEN 1/35-21 and ADQUEY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEMULEN 1/35-21 is classified as Category C. First trimester: increased risk of cardiovascular defects (RR ~1.3) and oral clefts (RR ~1.1) with exposure; second and third trimesters: no proven association with major malformat. ADQUEY is classified as Category C. ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Sec. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.